| Literature DB >> 25210853 |
Na-Young Shin1, Kyung-eun Kim1, Mina Park1, Young Dae Kim2, Dong Joon Kim1, Sung Jun Ahn1, Ji Hoe Heo2, Seung-Koo Lee1.
Abstract
BACKGROUND ANDEntities:
Mesh:
Year: 2014 PMID: 25210853 PMCID: PMC4161414 DOI: 10.1371/journal.pone.0107379
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Representative images of collateral status on dual-phase CT.
A, Some collaterals to the right MCA territory on CTA with persistence of some defects on CECT (Grade 1). B, Collaterals in part of the left MCA territory on CTA with complete filling on CECT (Grade 2). The collaterals show lower attenuation on CTA with equal to higher attenuation on CECT than unaffected vessels, suggesting slow inflow and washout of collaterals. C, Collaterals in the entire right MCA territory on both CTA and delayed CECT (Grade 3). The collateral vessels show attenuation similar to unaffected vessels on both phase images, suggesting fast velocity of collaterals.
Demographic characteristics according to dual-phase collateral status.
| Collateral status on dual-phase CT | |||||
| Incomplete (G1) (n = 10) | Slow-complete (G2) (n = 23) | Rapid-complete (G3) (n = 10) |
| Post-hoc analysis | |
| Age, y, mean ± SD | 75.9±6.8 | 70.1±10.7 | 61.1±11.4 | 0.010 | G1>G3 ( |
| Sex, n, M:F | 4:3 | 13:10 | 6:4 | 0.974‡ | |
| Risk factors | |||||
| Hypertension, n (%) | 9 (90.0) | 14 (60.9) | 1 (10.0) | 0.001‡ | G1>G3 ( |
| Diabetes, n (%) | 4 (40.0) | 5 (21.7) | 0 (0.0) | 0.109‡ | |
| Hypercholesterolemia, n (%) | 3 (30.0) | 2 (8.7) | 0 (0.0) | 0.147‡ | |
| Smoking, n (%) | 6 (60.0) | 8 (34.8) | 6 (60.0) | 0.302‡ | |
| Coronary artery disease, n (%) | 3 (30.0) | 10 (43.5) | 3 (30.0) | 0.763‡ | |
| Clinical measures at presentation | |||||
| SBP, mmHg, median (IQR) | 134.0 (111.0–161.0) | 135.0 (120.0–146.5) | 138.5 (112.0–149.0) | 0.947† | |
| DBP, mmHg, mean ± SD | 78.5 mmHg | 76.3 mmHg | 74.9 mmHg | 0.680 | |
| Glucose, mmol/L, median (IQR) | 7.25 (6.9–8.6) | 6.7 (5.7–8.3) | 7.1 (5.9–8.9) | 0.490† | |
| NIHSS score, median (IQR) | 16.5 (12.0–19.0) | 17.0 (14.3–19.0) | 14.0 (13.0–19.0) | 0.210† | |
| TOAST classification | 0.015‡ | ||||
| Large artery, n (%) | 1 (10.0) | 2 (8.7) | 6 (60.0) | ||
| Cardioembolic, n (%) | 7 (70.0) | 14 (60.9) | 4 (40.0) | ||
| Undetermined, n (%) | 2 (20.0) | 7 (30.4) | 0 (0.0) | ||
| CT | |||||
| Time from symptom onset to CT, min, mean ± SD | 170.9±106.6 | 209.0±91.1 | 170.0±87.1 | 0.415 | |
| ASPECTS, mean ± SD | 6.3±1.8 | 7.6±1.2 | 8.5±1.0 | 0.002 | G1<G2 ( |
| Occluded segment | |||||
| Intracranial ICA, n (%) | 5 (50.0) | 4 (17.4) | 0 (0.0) | 0.018‡ | |
| Proximal M1, n (%) | 7 (70.0) | 16 (69.6) | 7 (70.0) | 1.000‡ | |
| Distal M1, n (%) | 8 (80.0) | 20 (87.0) | 8 (80.0) | 0.753‡ | |
| Thrombus length, mm, median (IQR) | 19.3 (11.9–25.5) | 15.8 (8.6–18.5) | 11.0 (7.3–18.8) | 0.298† | |
| IV tPA | |||||
| IV tPA, n (%) | 5 (50.0) | 11 (47.8) | 8 (80.0) | 0.275. | |
| Time from symptom onset to IV tPA, min, mean ± SD | 77.8±20.6 | 108.6±41.4 | 91.4±38.2 | 0.301 | |
| TFCA | |||||
| TICI ≥ 2b, n (%) | 5 (50.0) | 5 (21.7) | 2 (20.0) | 0.264 | |
| Time from symptom onset to recanalization | 385.3±198.2 | 375.3±106.3 | 304.0±103.0 | 0.447 | |
| Outcome | |||||
| Final infarct volume, ml, median (IQR) | 91.1 (49.1–183.2) | 25.0 (10.3–76.7) | 12.3 (7.5–27.8) | 0.047 | G1>G2 ( |
| Symptomatic hemorrhage | 3 (30.0) | 3 (13.0) | 1 (10.0) | 0.537 | |
| parenchymal hematoma | 5 (50.0) | 4 (17.4) | 2 (20.0) | 0.199 | |
| 3m-mRS ≤ 2 | 0 (0.0) | 14 (60.9) | 9 (90.0) | <0.001 | G1<G2 ( |
ASPECTS indicates Alberta Stroke Program Early CT Score; DBP, diastolic blood pressure; IQR, Interquatile range; mRS, modified Rankin Score; NIHSS, National Institutes of Health Stroke Scale; SBP indicates systolic blood pressure; TICI, thrombolysis in cerebral infarction; TOAST, Trial of Org 10172 in Acute Stroke Treatment; and tPA, tissue plasminogen activator.
* one-way ANOVA; † Kruskal Wallis test; ‡ Fisher's exact test
Figure 2Clinical outcome according to collateral status.
All patients with incomplete collaterals showed unfavorable outcome at 3 months. Patients with complete collaterals had favorable clinical outcome more frequently than did patients with incomplete collaterals. * P = 0.003; ** P<0.001
Univariate analysis for favorable clinical outcome (mRS ≤2) at 3 months.
| Favorable (n = 23) | Unfavorable (n = 20) | Univariate analysis | |||
| Odds ratio | 95% CI |
| |||
| Age, y, mean ± SD | 66.1±10.2 | 73.4±11.0 | 0.934 | 0.874–0.997 | 0.040 |
| Male, n (%) | 16 (69.6) | 9 (45.0) | 2.794 | 0.800–9.760 | 0.107 |
| Risk factors | |||||
| Hypertension, n (%) | 9 (39.1) | 15 (75.0) | 0.214 | 0.058–0.797 | 0.022 |
| Diabetes, n (%) | 4 (17.4) | 5 (25.0) | 0.632 | 0.144–2.771 | 0.542 |
| Hypercholesterolemia, n (%) | 1 (4.3) | 4 (20.0) | 0.182 | 0.019–1.785 | 0.143 |
| Smoking, n (%) | 12 (52.2) | 8 (40.0) | 1.636 | 0.487–5.500 | 0.426 |
| Coronary artery disease, n (%) | 11 (47.8) | 5 (25.0) | 2.749 | 0.748–10.102 | 0.128 |
| Clinical measures at admission | |||||
| SBP, mmHg, median (IQR) | 135.0 (114.0–144.0) | 140.5 (113.5–163.5) | 0.980 | 0.956–1.005 | 0.114 |
| DBP, mmHg, mean ± SD | 73.5±11.0 | 79.9±17.3 | 0.967 | 0.924–1.013 | 0.157 |
| Glucose, mmol/L, median (IQR) | 6.7 (103.0–154.3) | 7.25 (121.0–152.5) | 1.028 | 0.793–1.334 | 0.833 |
| NIHSS score, median (IQR) | 15.0 (13.0–16.8) | 18.0 (15.5–19.0) | 0.873 | 0.747–1.020 | 0.088 |
| Delays | |||||
| Time from symptom onset to IV tPA, min, mean ± SD | 96.8±39.5 | 96.4±36.7 | 1.000 | 0.978–1.023 | 0.983 |
| Time from symptom onset to CT, min, mean ± SD | 198.0±95.7 | 183.0±93.2 | 1.002 | 0.995–1.008 | 0.596 |
| Time from symptom onset to IA treatment, min, mean ± SD | 268.2±107.9 | 259.2±113.8 | 1.001 | 0.995–1.006 | 0.785 |
| TOAST classification | |||||
| Large artery, n (%) | 7 (30.4) | 2 (10.0) | Reference | 0.286 | |
| Cardioembolic, n (%) | 12 (52.2) | 13 (65.0) | 0.264 | 0.046–1.528 | 0.137 |
| Undetermined, n (%) | 4 (17.4) | 5 (25.0) | 0.229 | 0.029–1.774 | 0.158 |
| CT | |||||
| ASPECTS, mean ± SD | 8.0±0.9 | 6.9±1.8 | 1.908 | 1.135–3.209 | 0.015 |
| CTA Collateral score | 2.0 (2.0–3.0) | 1.0 (1.0–2.0) | 6.077 | 1.926–19.167 | 0.002 |
| 0, n (%) | 0 (0.0) | 0 (0.0) | |||
| 1, n (%) | 4 (17.4) | 14 (70.0) | |||
| 2, n (%) | 12 (52.2) | 5 (25.0) | |||
| 3, n (%) | 7 (30.4) | 1 (5.0) | |||
| Dual-phase CT collateral score | 2.4±0.5 | 1.6±0.6 | 19.436 | 2.581–146.371 | 0.004 |
| 0, n (%) | 0 (0.0) | 0 (0.0) | |||
| 1, n (%) | 0 (0.0) | 10 (50.0) | |||
| 2, n (%) | 14 (60.9) | 9 (45.0) | |||
| 3, n (%) | 9 (39.1) | 1 (5.0) | |||
| Occluded segment | |||||
| Intracranial ICA, n (%) | 2 (8.7) | 7 (35.0) | 0.177 | 0.032–0.985 | 0.048 |
| Proximal M1, n (%) | 14 (60.9) | 16 (80.0) | 0.389 | 0.098–1.544 | 0.179 |
| Distal M1, n (%) | 20 (87.0) | 16 (80.0) | 1.667 | 0.325–8.549 | 0.540 |
| Thrombus length, mm, median (IQR) | 11.4 (7.4–17.6) | 17.9 (10.4–22.8) | 0.938 | 0.871–1.011 | 0.093 |
| Treatment | |||||
| IV tPA only, n (%) | 3 (13.0) | 0 (0.0) | Reference | 0.639 | |
| IA only, n (%) | 8 (34.8) | 11 (55.0) | 0.000 | 0.000 | 0.999 |
| IV tPA and IA, n (%) | 12 (52.2) | 9 (45.0) | 0.000 | 0.000 | 0.999 |
| TFCA | |||||
| TFCA collateral score | 3.0 (2.3–4.0) | 2.0 (1.0–2.0) | 3.092 | 1.537–6.221 | 0.002 |
| 0, n (%) | 0 (0.0) | 0 (0.0) | |||
| 1, n (%) | 2 (8.7) | 8 (40.0) | |||
| 2, n (%) | 4 (17.4) | 8 (40.0) | |||
| 3, n (%) | 6 (26.1) | 2 (10.0) | |||
| 4, n (%) | 11 (47.8) | 2 (10.0) | |||
| TICI ≥ 2b, n (%) | 4 (17.4) | 8 (40.0) | 0.316 | 0.078–1.282 | 0.107 |
| Time from symptom onset to recanalization, min, mean ± SD | 352.0±110.6 | 383.0±152.3 | 0.998 | 0.993–1.003 | 0.998 |
| Imaging outcome | |||||
| Final infarct volume, ml, median (IQR) | 13.7 (7.2–25.0) | 80.7 (34.0–144.8) | 0.965 | 0.943–0.988 | 0.003 |
| Symptomatic hemorrhage, n (%) | 1 (4.3) | 6 (30.0) | 0.106 | 0.012–0.977 | 0.048 |
| Parenchymal hematoma, n (%) | 3 (13.0) | 8 (40.0) | 0.225 | 0.050–1.016 | 0.052 |
ASPECTS indicates Alberta Stroke Program Early CT Score; DBP, diastolic blood pressure; IQR, Interquatile range; mRS, modified Rankin Score; NIHSS, National Institutes of Health Stroke Scale; SBP indicates systolic blood pressure; TFCA, transfemoral cerebral angiography; TICI, thrombolysis in cerebral infarction; TOAST, Trial of Org 10172 in Acute Stroke Treatment; and tPA, tissue plasminogen activator.
Multivariate analysis for favorable clinical outcome (mRS ≤2) at 3 months.
| Model 1 | Model 2 | Model 3 | |||||||
| Odds ratio | 95% CI |
| Odds ratio | 95% CI |
| Odds ratio | 95% CI |
| |
| Age | 0.969 | 0.880–1.067 | 0.520 | 0.953 | 0.877–1.035 | 0.250 | 0.958 | 0.879–1.044 | 0.332 |
| Hypertension | 2.682 | 0.294–24.508 | 0.382 | 1.435 | 0.187–10.993 | 0.728 | 1.164 | 0.171–7.939 | 0.877 |
| NIHSS score at admission | 0.814 | 0.648–1.023 | 0.077 | 0.868 | 0.731–1.029 | 0.103 | 0.826 | 0.678–1.006 | 0.058 |
| ASPECTS | 1.504 | 0.675–3.351 | 0.318 | 1.515 | 0.793–2.893 | 0.208 | 1.480 | 0.734–2.984 | 0.273 |
| Occlusion of intracranial ICA | 0.518 | 0.057–4.679 | 0.558 | 0.273 | 0.032–2.318 | 0.234 | 0.245 | 0.025–2.371 | 0.225 |
| Dual-phase CT collateral score | 27.117 | 1.519–484.258 | 0.025 | - | - | - | - | - | - |
| CTA collateral score | - | - | - | 4.456 | 0.929–21.365 | 0.062 | - | - | - |
| TFCA collateral score | - | - | - | - | - | - | 2.996 | 1.138–7.890 | 0.026 |
| AUC | 0.922 (0.798–0.981) | 0.880 (0.745–0.959) | 0.874 (0.737–0.955) | ||||||
ASPECTS indicates Alberta Stroke Program Early CT Score; AUC, area under the curve; ICA, internal carotid artery; and NIHSS, National Institutes of Health Stroke Scale.